View in EDS

ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.

Saved in:
Bibliographic Details
Title: ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.
Authors: Lozinski M; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.; Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia.; Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia., Bowden NA; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.; Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia., Graves MC; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.; Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia.; Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia., Fay M; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.; Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia.; Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia.; GenesisCare, Newcastle, NSW, Australia., Day BW; QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia., Stringer BW; Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD, Australia., Tooney PA; School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.; Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia.; Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia.
Source: Oncotarget [Oncotarget] 2024 Jan 16; Vol. 15, pp. 1-18. Date of Electronic Publication: 2024 Jan 16.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Electronic Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38227740
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lozinski+M%22">Lozinski M</searchLink>; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.; Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia.; Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Bowden+NA%22">Bowden NA</searchLink>; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.; Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Graves+MC%22">Graves MC</searchLink>; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.; Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia.; Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Fay+M%22">Fay M</searchLink>; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.; Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia.; Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia.; GenesisCare, Newcastle, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Day+BW%22">Day BW</searchLink>; QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.<br /><searchLink fieldCode="AU" term="%22Stringer+BW%22">Stringer BW</searchLink>; Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD, Australia.<br /><searchLink fieldCode="AU" term="%22Tooney+PA%22">Tooney PA</searchLink>; School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.; Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia.; Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101532965%22">Oncotarget</searchLink> [Oncotarget] 2024 Jan 16; Vol. 15, pp. 1-18. <i>Date of Electronic Publication: </i>2024 Jan 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Impact+Journals%22">Impact Journals </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101532965 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1949-2553 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219492553%22">19492553 </searchLink><i>NLM ISO Abbreviation: </i>Oncotarget <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38227740
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.18632/oncotarget.28551
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1
    Titles:
      – TitleFull: ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lozinski M
      – PersonEntity:
          Name:
            NameFull: Bowden NA
      – PersonEntity:
          Name:
            NameFull: Graves MC
      – PersonEntity:
          Name:
            NameFull: Fay M
      – PersonEntity:
          Name:
            NameFull: Day BW
      – PersonEntity:
          Name:
            NameFull: Stringer BW
      – PersonEntity:
          Name:
            NameFull: Tooney PA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 16
              M: 01
              Text: 2024 Jan 16
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1949-2553
          Numbering:
            – Type: volume
              Value: 15
          Titles:
            – TitleFull: Oncotarget
              Type: main
ResultId 1